Top Insights
Health
globalreutersSeptember 15, 20241 Mins read
Roche Welcomes FDA Approvals for Injectable Versions of MS and Cancer Drugs
globalreutersSeptember 15, 20241 Mins read 
Roche’s Tecentriq Hybreza is a subcutaneously injectable formulation of the cancer drug Tecentriq while Ocrevus Zunovo is an injectable version of multiple sclerosis drug Ocrevus. Each is administered in minutes compared to an hour or more for infused therapies.
The post Roche Welcomes FDA Approvals for Injectable Versions of MS and Cancer Drugs appeared first on MedCity News.
Related Articles
What you need to know about Limb Amputation Surgery: Causes, Risks, and Recovery?
Have you ever wondered what happens when a limb Amputation is a...
Links
Employee opinions on their health insurance. Republican vs. Democratic physicians. States’ perspective...
There’s an Opportunity for More Providers to Partner with the 988 Lifeline, Execs Say
Two executives at behavioral health care companies discussed why it’s important for...
Media Call: What a Second Trump Administration May Mean for Health Care
Former President Trump’s return to the White House in 2025 could bring...
Leave a comment